



Neu-QAP

(an EXTERNAL QUALITY ASSURANCE PROGRAMME)

PARTICIPANT FINAL ASSESSMENT REPORT

PT SCHEME: SEROLOGY



PC-1047

Cycle No	C3
Ref.No.	NEUQAP109
Sample ID	NEUQAP SERO SERUM/2021/7/C3/S3

Report Date : 10/08/2021

Sample : July 2021

All Methods

Parameters	Lab Report	No of Participants	Consensus Report	%	Remarks
Brucella	Not Recvd.	24	Non Reactive - 24		
Brucella Antigen	Not Recvd.	3	Non Reactive - 3		
Brucella IgG	Not Recvd.	17	Non Reactive - 17		
Brucella IgM	Not Recvd.	18	Non Reactive - 18		
Chikungunya	Not Recvd.	42	Negative - 41		
			Positive - 1		
CMV IgG	Not Recvd.	42	Reactive - 42		
CMV IgM	Not Recvd.	43	Non Reactive - 43		
HBsAg	Reactive	91	Non Reactive - 4		
			Reactive - 87	96	Within Consensus
HCV	Reactive	91	Non Reactive - 16		
			Reactive - 75	82	Within Consensus
HIV-1	Reactive	91	Non Reactive - 1		
			Reactive - 90	99	Within Consensus
RPR	Reactive	88	Non Reactive - 68		
			Reactive - 20		Out of Consensus
Rubella IgG	Not Recvd.	41	Reactive - 41		
Rubella IgM	Not Recvd.	39	Non Reactive - 39		
Toxoplasma IgG	Not Recvd.	40	Non Reactive - 1		
			Reactive - 39		
Toxoplasma IgM	Not Recvd.	39	Non Reactive - 39		
Weil Felix OX19	Not Recvd.	36	Negative - 35		
			Positive - 1		

Authorised Signatory

Dr. Sujay Prasad

Technical Manager and Program coordinator

Page 1 of 3

This report is for use only by the intended participant.



An external quality assurance program from
NEUBERG ANAND ACADEMY OF LABORATORY MEDICINE PVT.LTD.

Anand Tower, 54, Bowring Hospital Road,
Shivajinagar, Bangalore - 560001
+91-9902277355 · qap@naalm.com · www.naalm.com
CIN: U85300KA2018PTC115147



Neu-QAP

(an EXTERNAL QUALITY ASSURANCE PROGRAMME)

PARTICIPANT FINAL ASSESSMENT REPORT

PT SCHEME: SEROLOGY



Cycle No	C3
Ref.No.	NEUQAP109
Sample ID	NEUQAP SERO SERUM/2021/7/C3/S3

Report Date : 10/08/2021

Sample : July 2021

All Methods

Parameters	Lab Report	No of Participants	Consensus Report	%	Remarks
Weil Felix OX2	Not Recvd.	37	Negative - 35		
			Positive - 2		
Weil Felix OXK	Not Recvd.	36	Negative - 34		
			Positive - 2		
Widal	Negative	65	Negative - 65	100	Within Consensus

Authorised Signatory

Dr. Sujay Prasad

Technical Manager and Program coordinator

Page 2 of 3

This report is for use only by the intended participant.



An external quality assurance program from
NEUBERG ANAND ACADEMY OF LABORATORY MEDICINE PVT.LTD.

Anand Tower, 54, Bowring Hospital Road,
Shivajinagar, Bangalore - 560001
+91-9902277355 · qap@naalm.com · www.naalm.com
CIN: U85300KA2018PTC115147



Neu-QAP

(an EXTERNAL QUALITY ASSURANCE PROGRAMME)

PARTICIPANT FINAL ASSESSMENT REPORT

PT SCHEME: SEROLOGY



PC-1047

Cycle No	C3
Ref.No.	NEUQAP109
Sample ID	NEUQAP SERO SERUM/2021/7/C3/S3

Report Date : 10/08/2021

Sample : July 2021

Peer group

Parameters	Lab Report	No of Participants	Consensus Report	%	Remarks
HBsAg (Card Method)	Reactive	13	Non Reactive - 2	85	Within Consensus
			Reactive - 11		
HCV (Card method)	Reactive	15	Non Reactive - 10		Out of Consensus
			Reactive - 5		
HIV-1 (Card method)	Reactive	11	Non Reactive - 1	91	Within Consensus
			Reactive - 10		
RPR (--OTHERS--)	Reactive	2	Reactive - 2	100	Within Consensus
Widal (Slide agglutination)	Negative	20	Negative - 20	100	Within Consensus

Note: Sample generation, homogeneity and stability testing are subcontracted to accredited laboratories

**End of report **

Authorised Signatory

Dr. Sujay Prasad

Technical Manager and Program coordinator

Page 3 of 3

This report is for use only by the intended participant.



An external quality assurance program from
NEUBERG ANAND ACADEMY OF LABORATORY MEDICINE PVT.LTD.

Anand Tower, 54, Bowring Hospital Road,
Shivajinagar, Bangalore - 560001
+91-9902277355 · qap@naalm.com · www.naalm.com
CIN: U85300KA2018PTC115147